Optum Rx (UnitedHealthcare)
PBM standard commercial template (Premium Standard Formulary) · updated October 13, 2026
Coverage right now
- Foundayo™ (orforglipron) Varies
- Saxenda® (liraglutide) Covered
- Wegovy® (semaglutide injection) Covered
- Wegovy® tablets (oral semaglutide) Varies
- Zepbound® (tirzepatide) Covered
Kept both Wegovy and Zepbound covered throughout 2025-2026 — no CVS-style exclusion — with PA + quantity limits throughout, though Zepbound is covered as the auto-injector only and the vials are excluded outright. Tier placement is a plan-level answer rather than a property of the formulary: booklets carrying the same 'Premium Standard Formulary' name and the same Jan 1 2026 effective date print these drugs at Tier 2 in one case and Tier 3 in another. Weight-loss coverage is an opt-in employer benefit. Foundayo joined the weight-loss PA policy on 9/1/2026 but has no published formulary tier and may be excluded at launch on some plans.
Drug status
| Drug | Status | Detail | Confidence |
|---|---|---|---|
| Zepbound® (tirzepatide) | Covered from Jan 1, 2026 | Tier 2, PA + QL — but only as the auto-injector: the booklet prints ZEPBOUND SUBCUTANEOUS SOLUTION AUTO-INJECTOR at Tier 2 and the plain ZEPBOUND SUBCUTANEOUS SOLUTION — the vials — as E, excluded. Device-level steering, the same shape as the Express Scripts KwikPen/vial exclusion. On the OSA pathway, read the policy that governs the request rather than the trade press: P 1114-23 lists 'Zepbound is being requested for moderate to severe obstructive sleep apnea' as one of its four indication routes and asks for no sleep study and no CPAP trial, while still applying the same BMI bar, age bar and lifestyle adjunct as the weight-loss route -- so unlike some payers, OSA here does not get you past BMI >= 30 or >= 27 with a comorbidity. Its own P&T history dates the Zepbound OSA addition to 3/2025, not the July 2025 the secondary source gives. The sleep-study and CPAP requirements previously recorded here belong to a different document, P 1475-1, which is not cited in this file and has only ever been described to us second-hand. source | medium |
| Wegovy® (semaglutide injection) | Covered from Jan 1, 2026 | Tier 2, PA + QL. source | medium |
| Wegovy® tablets (oral semaglutide) | Covered from Jul 1, 2026 to Sep 30, 2026 | Covered under the weight-loss PA policy (P 1114-22 covers Wegovy injection and tablet); tier placement not shown in the Jan 2026 booklet. The policy footnotes Wegovy tablet as a product that 'may be in Exclude at Launch', so some plans may not cover it yet. source | medium |
| Wegovy® tablets (oral semaglutide) | Varies from Oct 1, 2026 | Policy P 1114-23, effective 10/1/2026, states in its own words: 'Wegovy tablets are typically excluded from coverage.' That replaces the softer 'may be in Exclude at Launch' footnote the policy carried through September, so this is a plan-level answer that now leans against coverage rather than merely being undecided. The tablet is still named throughout the criteria — a 5-month initial authorization, a 12-month reauthorization, and eligibility for both the weight-loss and the cardiovascular-risk-reduction indications — so a plan that does cover it has published criteria to approve against. No formulary tier is published for it. source | high |
| Foundayo™ (orforglipron) | Unknown | Absent from the Jan 2026 formulary booklet and the 7/1/2026 UHC weight-loss PA drug list — suggests non-formulary / new-to-market review as of Aug 2026. Verify with your plan. source | low |
| Foundayo™ (orforglipron) | Varies from Sep 1, 2026 to Sep 30, 2026 | Named in the weight-loss PA policy (P 1114-22) from 9/1/2026: initial authorization 6 months, reauthorization 12 months. The policy footnotes Foundayo and Wegovy tablet as products that 'may be in Exclude at Launch', so whether a given plan covers it at all is a plan-level answer. Still absent from the 2026 Premium Standard Formulary booklet, so no tier is published. source | high |
| Foundayo™ (orforglipron) | Varies from Oct 1, 2026 | Named in the weight-loss PA policy (P 1114-23) effective 10/1/2026: initial authorization 6 months, reauthorization 12 months. The launch-exclusion footnote is gone — the 8/2026 revision removed the note that Foundayo may be excluded at launch, and kept one only for Wegovy tablets — so Foundayo now sits in the criteria on the same footing as Zepbound and Saxenda. It remains STATUS_VARIES for two reasons that have nothing to do with the drug: no formulary tier is published for it in the 2026 Premium Standard Formulary booklet, and whether a plan covers weight-loss medication at all is an employer opt-in under this program. source | high |
| Saxenda® (liraglutide) | Covered from Jan 1, 2026 | Tier 2, PA + QL. source | medium |
What these rules come to in dollars — every dose, priced under this coverage:
- Foundayo 0.8 mg2.5 mg5.5 mg9 mg14.5 mg17.2 mg
- Wegovy 0.25 mg0.5 mg1 mg1.7 mg2.4 mg7.2 mg
- Wegovy® tablets 1.5 mg4 mg9 mg25 mg
- Zepbound 2.5 mg5 mg7.5 mg10 mg12.5 mg15 mg
What preferred, covered and exception only mean
- Preferred
- On the formulary at the plan's best tier for this class. Usually still needs prior authorization — preferred is not the same as automatic.
- Covered
- On the formulary, but not the plan's first choice for this class. Often a higher copay tier than a preferred drug.
- Non preferred
- On the formulary at a disadvantaged tier, or reachable only after trying a preferred drug first.
- Exception only
- Not routinely covered. Obtainable only through a formulary-exception request that meets the plan's published criteria.
- Excluded
- Not on the formulary at all. A benefit exclusion is a different fight from a PA denial and is appealed differently.
- Varies
- The payer's own documents differ by plan or line of business, so a single answer here would be wrong.
- Unknown
- Not yet verified against a primary document. Recorded as absent rather than guessed.
- N/A
- Not applicable to this payer.
Prior authorization criteria
high- PA required
- Yes (PA + QL flags on formulary), under program P 1114-23 effective 10/1/2026. Your benefit plan decides whether weight-loss medications are covered at all -- this is an optional program clients elect into. That is not the dead end it reads as: P 1114-23 footnotes three of its four indication routes to a separate criteria set for plans that do NOT cover weight-loss medication, naming 'Nonformulary Wegovy criteria' against the cardiovascular and MASH routes and 'Nonformulary Zepbound criteria' against the sleep-apnea route. So a plan without the weight-loss benefit still has published criteria for a GLP-1 requested on a non-weight indication. Those two documents have not been located to read, so what they require is unknown here -- ask Optum Rx for the nonformulary criteria by name rather than accepting the absence of the weight-loss benefit as the answer.
- Initial BMI
- BMI >= 30 (pediatric: > 95th percentile), OR BMI >= 27 with a documented weight-related comorbidity, OR no BMI threshold at all where Wegovy injection is requested for MASH — the 4/2026 revision made that carve-out explicit. The pediatric route is not open on every drug: the policy sets a minimum age of >= 12 for Wegovy injection, Saxenda, Qsymia and Xenical, and > 16 for every other listed product — which includes Zepbound, Foundayo, Wegovy tablet and Wegovy HD.
- Comorbidities
- Dyslipidemia, hypertension, type 2 diabetes, sleep apnea.
- Lifestyle requirement
- Used as an adjunct to lifestyle modification (dietary/caloric restriction, exercise, behavioral support, community program). Continuation required at reauth. No minimum duration stated — the loosest lifestyle requirement among the big three.
- Initial authorization
- Wegovy (inj/tablet)/Wegovy HD 5 · Zepbound/Foundayo/Xenical 6 · Saxenda/Contrave/Qsymia 4
- Reauthorization
- >= 5% of baseline weight for Wegovy/Zepbound (Saxenda >= 4%, Qsymia >= 3%). Reauthorization lasts 12 months. P 1114-23 adds a second way to pass it: for Foundayo, Saxenda, Wegovy injection or tablet and Zepbound, a patient who has been on therapy for six months or less and has not yet reached a maintenance dose gets a one-time 6-month authorization instead, with no weight-loss figure required. Continuation of lifestyle modification is required either way. The MASH route for Wegovy injection is judged on fibrosis response and absence of cirrhosis rather than on weight.
- Step therapy
- None documented — no trial-and-failure of other anti-obesity medications required.
- Quantity limits
- QL flag applies; specific per-days quantities not published in retrieved documents.
Primary criteria document: uhcprovider.com
Exceptions and appeals
- Appeal deadline
- 180 days
- Deadline detail
- 180 days internal appeal (commercial, per denial letter / ERISA standard).
- Exception route
- Prescriber ePA via professionals.optumrx.com. Verbal PA / urgent line 1-800-711-4555 (5am-10pm PT M-F). Fax retired except MA/RI/SC/TX.
- Turnaround
- Not published by Optum Rx. Secondary reporting: electronic decisions from seconds up to 72 hours; 1-2 weeks for manual submissions.
- Where
- Per your denial letter (plan-specific).
Source: business.optum.com
Dated changes
- Jul 1, 2025 UHC added Zepbound OSA pathway (policy P 1475-1) source
- Jan 1, 2026 2026 Premium formulary exclusions (12 drugs) included no GLP-1 changes source
- Jul 1, 2026 Weight-loss PA policy updated (P 1114-21): adds Wegovy tablet, MASH pathway source
- Sep 1, 2026 Weight-loss PA policy P 1114-22 adds Foundayo (orforglipron) to the covered drug list at 6 months initial authorization, footnoted as possibly excluded at launch on some plans source
- Oct 1, 2026 Weight-loss PA policy P 1114-23 drops the launch-exclusion footnote from Foundayo, hardens the Wegovy tablet footnote to 'typically excluded from coverage', and adds a one-time 6-month reauthorization for patients not yet at a maintenance dose source